Revamping Medical Regulations: A Call for Comprehensive Reform

By HEOR Staff Writer

November 16, 2023

The Regulatory Hurdle

Europe’s healthcare system, known for its extensive social security and fair healthcare access, faces a test of strength. Structural barriers in the existing regulatory framework hinder the prompt distribution of vital medical technologies. These technologies are crucial at every patient care stage.


The In Vitro Diagnostic Medical Devices Regulation (IVDR) and Medical Devices Regulation (MDR) were designed with the objective of creating a robust, transparent, predictable, and sustainable regulatory system for medical devices. The expectation was that these regulations would foster innovation while ensuring high levels of safety and health. However, more than half a decade into their implementation, the IVDR and MDR have fallen short of achieving these goals. The result is a sluggish, unpredictable, costly, and intricate process.

The Call for Medical Device Regulations Reform

MedTech Europe, a prominent representative of the medical technology industry, advocates for a comprehensive overhaul of the regulations to make them more beneficial for patients and European health systems. This reform should focus on three main areas: efficiency, innovation, and governance.

Efficiency: MedTech Europe suggests a more streamlined and cost-effective CE marking system. This system should enhance predictability, lessen administrative burdens, and be adaptable to external changes.

Innovation: The implementation of an innovation principle is advised. This would expedite the integration of the latest medical technologies into European healthcare systems, through the use of specific assessment pathways and early dialogues with developers.

Governance: The creation of a singular, dedicated structure to supervise and manage the regulatory system is recommended. This structure should have the power to make decisions at the system level.

Conclusion

To ensure that Europe maintains its high standards of care, and continues to leverage innovative medical technology, it is crucial to reform the existing regulatory framework. The solutions proposed by MedTech Europe provide a starting point for discussions among all stakeholders, with the aim of addressing the current challenges and reshaping the future of Europe’s healthcare system.

Reference url

Recent Posts

Harmonizing Non-Clinical Evaluation of Microbiome Medicinal Products in the EU

By João L. Carapinha

March 4, 2026

EMA's Push for Microbiome Medicinal Products Guidance EMA's Non-Clinical Working Party has drafted a concept paper, adopted by CHMP on 16 February 2026, proposing a reflection paper to guide non-clinical development of microbiome...
Tirzepatide Cost Effectiveness: A Winning Strategy for Type 2 Diabetes Management

By João L. Carapinha

March 3, 2026

Tirzepatide Cost Effectiveness in UK T2D Care Evaluating tirzepatide cost effectiveness reveals significant advantages over semaglutide 1 mg for patients with type 2 diabetes (T2D) inadequately controlled on metformin, based on a
CHMP February 2026 Approvals: New Breakthroughs in Medicines and Biosimilars
CHMP February 2026 Approvals: 12 New Medicines and Biosimilars Advance The CHMP Febru...